HAIFA, Israel - Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm specializing in cell-based solutions, has entered a manufacturing agreement with Remedy Cell Ltd. Through its contract development and manufacturing organization (CDMO) division, PluriCDMO™, the company will produce clinical-grade materials for Remedy Cell's RC-0315, a drug candidate aimed at treating Idiopathic Pulmonary Fibrosis (IPF).
Remedy Cell, a biopharmaceutical company focused on cell-derived therapies for fibrotic diseases, is developing RC-0315 to address the severe unmet medical needs of IPF patients. IPF is a fatal lung condition with limited treatment options, characterized by scarring of the lung tissue and an average life expectancy post-diagnosis of 3.8 years.
Under the agreement, PluriCDMO™ will assist in creating a Working Cell Bank (WCB) and Good Manufacturing Practice (GMP) batches of RC-0315, which is derived from mesenchymal stem cells. This collaboration is set to support the launch of Remedy Cell's Phase Ib clinical trial.
Ayelet Dilion-Mashiah, CEO of Remedy Cell, expressed optimism about the partnership, highlighting Pluri's expertise in cell therapy development and manufacturing as a catalyst for quicker market entry.
Yaky Yanay, CEO and President of Pluri, also commented on the partnership, expressing enthusiasm for supporting Remedy Cell's innovative treatments and the potential for a long-term collaboration.
Pluri's technology platform includes a patented 3D cell expansion system that claims to offer accuracy, scalability, and cost-efficiency. The company aims to extend its cell-based technology to various industries beyond regenerative medicine, food-tech, and agtech.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.